Apollon Formularies (AQSE:APOL) EV-to-EBIT : -2.66 (As of May. 17, 2024)

View and export this data going back to . Start your Free Trial

What is Apollon Formularies EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Apollon Formularies's Enterprise Value is £1.07 Mil. Apollon Formularies's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.40 Mil. Therefore, Apollon Formularies's EV-to-EBIT for today is -2.66.

The historical rank and industry rank for Apollon Formularies's EV-to-EBIT or its related term are showing as below:

AQSE:APOL' s EV-to-EBIT Range Over the Past 10 Years
Min: -41.17 Med: -0.76 Max: 0.34
Current: -2.66

During the past 11 years, the highest EV-to-EBIT of Apollon Formularies was 0.34. The lowest was -41.17. And the median was -0.76.

AQSE:APOL's EV-to-EBIT is ranked worse than
100% of 667 companies
in the Drug Manufacturers industry
Industry Median: 17.59 vs AQSE:APOL: -2.66

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Apollon Formularies's Enterprise Value for the quarter that ended in Jun. 2023 was £1.30 Mil. Apollon Formularies's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.40 Mil. Apollon Formularies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -31.03%.

Apollon Formularies EV-to-EBIT Historical Data

The historical data trend for Apollon Formularies's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies EV-to-EBIT Chart

Apollon Formularies Annual Data

Trend

Jun10

Jun11

Dec12

Dec13

Dec14

Dec17

Dec18

Dec19

Dec20

Dec21

EV-to-EBIT

Get a 7-Day Free Trial

0.32

-4.63

-4.97

-7.73

Apollon Formularies Semi-Annual Data
	Jun11	Jun12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec17	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Jun23
EV-to-EBIT	Get a 7-Day Free Trial											-4.97	-	-7.73	-	-

Competitive Comparison of Apollon Formularies's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Apollon Formularies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Apollon Formularies's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Apollon Formularies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Apollon Formularies's EV-to-EBIT falls into.

Apollon Formularies EV-to-EBIT Calculation

Apollon Formularies's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	1.072	/	-0.403
	=	-2.66

Apollon Formularies's current Enterprise Value is £1.07 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Apollon Formularies's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.40 Mil.

Apollon Formularies (AQSE:APOL) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Apollon Formularies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jun. 2023 )	=	EBIT	/	Enterprise Value (Q: Jun. 2023 )
	=	-0.403	/	1.29858425
	=	-31.03 %

Apollon Formularies's Enterprise Value for the quarter that ended in Jun. 2023 was £1.30 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Apollon Formularies's EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was £-0.40 Mil.

Apollon Formularies EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Apollon Formularies (AQSE:APOL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS

Website

https://www.apollon.org.uk

Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.